WO1998008500A1 - Hypertonic arginine compositions and methods - Google Patents
Hypertonic arginine compositions and methods Download PDFInfo
- Publication number
- WO1998008500A1 WO1998008500A1 PCT/US1997/016203 US9716203W WO9808500A1 WO 1998008500 A1 WO1998008500 A1 WO 1998008500A1 US 9716203 W US9716203 W US 9716203W WO 9808500 A1 WO9808500 A1 WO 9808500A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hemoglobin
- arginine
- hypertonic
- composition
- mosm
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims abstract description 18
- 239000004475 Arginine Substances 0.000 title claims description 30
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title claims description 29
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 80
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 80
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 46
- 229930064664 L-arginine Natural products 0.000 claims abstract description 41
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 41
- 208000014674 injury Diseases 0.000 claims abstract description 19
- 230000008733 trauma Effects 0.000 claims abstract description 13
- 230000002685 pulmonary effect Effects 0.000 claims abstract description 4
- 208000002815 pulmonary hypertension Diseases 0.000 claims abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 63
- 235000002639 sodium chloride Nutrition 0.000 claims description 42
- 239000011780 sodium chloride Substances 0.000 claims description 36
- 235000009697 arginine Nutrition 0.000 claims description 26
- 206010047139 Vasoconstriction Diseases 0.000 claims description 16
- 230000025033 vasoconstriction Effects 0.000 claims description 16
- 239000003633 blood substitute Substances 0.000 claims description 15
- 229920002307 Dextran Polymers 0.000 claims description 14
- 239000000084 colloidal system Substances 0.000 claims description 14
- 208000001953 Hypotension Diseases 0.000 claims description 9
- 230000036543 hypotension Effects 0.000 claims description 8
- 230000035939 shock Effects 0.000 claims description 8
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 6
- 238000007675 cardiac surgery Methods 0.000 claims description 4
- 229940027278 hetastarch Drugs 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 201000006474 Brain Ischemia Diseases 0.000 claims description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 230000018044 dehydration Effects 0.000 claims description 3
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- 108010049645 liposome-encapsulated hemoglobin Proteins 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- 206010021138 Hypovolaemic shock Diseases 0.000 claims description 2
- 230000008642 heat stress Effects 0.000 claims description 2
- 206010040560 shock Diseases 0.000 claims description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 4
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 2
- 239000001632 sodium acetate Substances 0.000 claims 2
- 235000017281 sodium acetate Nutrition 0.000 claims 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 2
- 229940005581 sodium lactate Drugs 0.000 claims 2
- 235000011088 sodium lactate Nutrition 0.000 claims 2
- 239000001540 sodium lactate Substances 0.000 claims 2
- 239000003058 plasma substitute Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 26
- 239000001301 oxygen Substances 0.000 abstract description 26
- 229910052760 oxygen Inorganic materials 0.000 abstract description 26
- 238000009472 formulation Methods 0.000 abstract description 20
- 238000001802 infusion Methods 0.000 abstract description 19
- 210000004556 brain Anatomy 0.000 abstract description 15
- 208000032843 Hemorrhage Diseases 0.000 abstract description 11
- 230000005796 circulatory shock Effects 0.000 abstract description 6
- 239000013011 aqueous formulation Substances 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 210000000278 spinal cord Anatomy 0.000 abstract 1
- 208000037905 systemic hypertension Diseases 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 64
- 208000030886 Traumatic Brain injury Diseases 0.000 description 30
- 230000009529 traumatic brain injury Effects 0.000 description 30
- 230000003727 cerebral blood flow Effects 0.000 description 23
- 230000000694 effects Effects 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 230000000747 cardiac effect Effects 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 230000036772 blood pressure Effects 0.000 description 10
- 230000004872 arterial blood pressure Effects 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 7
- 206010049771 Shock haemorrhagic Diseases 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 239000001272 nitrous oxide Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 206010058558 Hypoperfusion Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241001494479 Pecora Species 0.000 description 5
- 208000005247 Traumatic Brain Hemorrhage Diseases 0.000 description 5
- 239000000819 hypertonic solution Substances 0.000 description 5
- 229940021223 hypertonic solution Drugs 0.000 description 5
- 238000007917 intracranial administration Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000001839 systemic circulation Effects 0.000 description 4
- 230000000304 vasodilatating effect Effects 0.000 description 4
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 3
- 206010065384 Cerebral hypoperfusion Diseases 0.000 description 3
- 230000008344 brain blood flow Effects 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000004088 pulmonary circulation Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000005156 Dehydration Diseases 0.000 description 2
- 241001269524 Dura Species 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021137 Hypovolaemia Diseases 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010047163 Vasospasm Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000001627 cerebral artery Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- -1 for example Chemical class 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 229940064366 hespan Drugs 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000036593 pulmonary vascular resistance Effects 0.000 description 2
- 230000008695 pulmonary vasoconstriction Effects 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- NPJMDBHUQHLEPR-FHNDMYTFSA-M sodium;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;chloride Chemical compound [Na+].[Cl-].OC(=O)[C@@H](N)CCCN=C(N)N NPJMDBHUQHLEPR-FHNDMYTFSA-M 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- PREOBXYMXLETCA-UHFFFAOYSA-N 2-[4-(2-carboxyphenoxy)-4-oxobutanoyl]oxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC(=O)CCC(=O)OC1=CC=CC=C1C(O)=O PREOBXYMXLETCA-UHFFFAOYSA-N 0.000 description 1
- INZBQWPDNWVYFR-OWOJBTEDSA-N 3,5-dibromo-2-[(e)-4-(2,4-dibromo-6-carboxyphenoxy)-4-oxobut-2-enoyl]oxybenzoic acid Chemical compound OC(=O)C1=CC(Br)=CC(Br)=C1OC(=O)\C=C\C(=O)OC1=C(Br)C=C(Br)C=C1C(O)=O INZBQWPDNWVYFR-OWOJBTEDSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 229930028154 D-arginine Natural products 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 241000892865 Heros Species 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 241000231739 Rutilus rutilus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- 206010071090 Transfusion related complication Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000002978 anti-vasoconstrictor Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000001490 effect on brain Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 208000011316 hemodynamic instability Diseases 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000000076 hypertonic saline solution Substances 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000003088 neuroexcitatory effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- VRYGRLBNIVQXMY-UHFFFAOYSA-M sodium;acetic acid;chloride Chemical compound [Na+].[Cl-].CC(O)=O VRYGRLBNIVQXMY-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000009104 vascular sensitivity Effects 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
Definitions
- the present invention relates generally to the field of medical treatment. More particularly, it relates to improved hyperosmotic compositions for the treatment of hypovolemia, circulatory shock, traumatic brain injury (TBI), and hypoperfusion of the brain. Some of the hyperosmotic compositions include hemoglobin or various blood substitutes and others are hyperosmotic compositions without hemoglobin.
- the invention also concerns methods for prevention and treatment to reduce pulmonary and systemic vasoconstriction associated with infusion of hemoglobin solutions.
- Hemorrhage, hypovolemia, circulatory shock and trauma are common life threatening medical emergencies resulting from accidents, crime, terrorism, and war.
- Reduced blood volume lowers the blood pressure and cardiac output and oxygen delivery to critical organs in turn causing ischemia, organ dysfunction, and death.
- the brain is sensitive to ischemia and becomes particularly so when TBI accompanies hemorrhagic shock.
- TBI cerebral blood flow
- CDO 2 cerebral oxygen delivery
- ICP intracranial pressure
- MAP mean arterial pressure
- a goal of shock resuscitation therapy is to improve the CBF and oxygen delivery to the brain and other tissues. Ideal therapy, yet to be achieved, for TBI would be to lower the ICP, selectively vasodilate the brain, and correct and prevent hypotension and hemorrhagic shock.
- hemoglobin as an oxygen carrier emphasizes the need for red blood cell substitutes.
- Large quantities of blood are used daily in emergency care and surgery.
- Natural disasters and war casualties demand immediate availability of blood. Avoiding blood transfusion is a high priority because of the related potentially fatal side effects, including transmission of infectious diseases and transfusion reactions.
- advantages of blood substitutes include their role as a universal blood substitute for surgery and trauma without the need for cross-match interference. Other advantages would be long storageability, immediate availability, lack of viral or bacterial exposures, and moderate cost.
- oxygen-carrying capacity several studies have shown pressor and perfusion properties of stroma-free hemoglobins when used in animal models of hemorrhagic shock or in whole blood exchange.
- vasoconstrictor effect include: activation and release of endothelin, enhanced vascular sensitivity of the alpha-adrenergic receptors to circulating catecholamines, and release of platelet activator factor or related compounds (Poli de Figueiredo and Mathru, 1997).
- the present invention relates to new hypertonic arginine formulations that effectively correct cerebral ischemia and hypoxia of the combined injury of TBI and hemorrhage.
- the disclosed resuscitation solutions particularly when used in combination with hemoglobin or hemoglobin substitutes, would reduce or eliminate the vasoconstrictive properties of hemoglobin, diminishing the likelihood of vasoconstriction related complications and more effectively treating shock and trauma. These formulations thus address several significant problems in treating hemorrhagic shock, particularly where TBI is involved.
- the disclosed methods employing hypertonic arginine formulations are expected to have a significant societal and economic benefit in reducing the morbidity and mortality of TBI.
- L-arginine would have predicted lower blood pressure by producing more vasodilation through greater NO release. Use of L-arginine therefore would seem to be contra-indicated in treatment of hypotensive shock.
- the invention in an important aspect relates to methods of treating hypovolemic shock and particularly to those types of shock that are associated with multifocal trauma such as where traumatic brain injury (TBI) is involved.
- TBI traumatic brain injury
- L-arginine formulations in hypertonic media have been shown to have a surprising effect on brain blood flow by increasing brain blood flow while at the same time maintaining much lower intracranial pressure than lactated Ringers, a commonly used solution for increasing blood volume, or hypertonic saline.
- lactated Ringers a commonly used solution for increasing blood volume, or hypertonic saline.
- a NaCl hypertonic solution containing L-arginine was used. This solution had an osmolarity of about 2,400 mOsm/L and on intravenous infusion delivered a dose of arginine in excess of 50 mg/kg in an infused volume of 4-6 ml/kg.
- suitable osmolalities may include from about 1000 mOsm/L up to about 5,000 with 1,500 to 3,000 being particularly preferred.
- Hypertonic solutions are not limited to ionic NaCl solutes and may include NaAcetate, Mannitol or other physiologically acceptable salts, carbohydrates or amino acids.
- L-arginine formulations may include ionic or nonionic species such as ATP-MgCl, fructose diphosphate or dichloroacetate.
- hyperoncotic colloids for example, dextran, hetastarch, proteins or peptides, hemoglobin or hemoglobin substitutes.
- hemoglobins several are known and available, including cell free human or animal hemoglobin, cross-linked hemoglobin, acellular alpha or beta chain cross-linked hemoglobin, recombinant hemoglobin, polymerized hemoglobin, PEG conjugated hemoglobin, bovine hemoglobin, hemoglobin conjugated with dextrans and liposome- encapsulated hemoglobin.
- L-arginine is delivered in hypertonic media at a dose of at least 50 mg/kg in an infused volume of at least 3 ml/kg and preferably higher; for example, at 4-6 ml/kg.
- a preferred embodiment is a hypertonic solution of L-arginine that includes hemoglobin or hemoglobin substitute.
- hypertonic L-arginine solutions significantly improve CBF and normalize cardiac output while reducing vasoconstriction in systemic and pulmonary circulation. These beneficial effects may be obtained by combining the hypertonic L-arginine formulations with hemoglobin, or alternatively, infusing separately with a hemoglobin or hemoglobin substitute.
- preferred effective concentrations are in the range of about 0.3 to about 7.5 g/100 ml. Where NaCl is used as the hypertonic medium, preferred ranges are about 6 to about 8 g/100 ml.
- osmolality of the solutions are generally in the 1 ,000-2,400 mOsm range; however, this is not to say that ranges from about 800 to about 5000 mOsm/L would not also be beneficial in certain applications.
- a convenient method to adjust osmolarity is to add or remove water.
- FIG. 1A shows changes in CBF of anesthetized rats subjected to TBI and hemorrhage after a 6 ml/kg treatment with -2400 mOsm Arginine-NaCl solution made up of 7.28 g/100 ml NaCl and 1.67 g L-arginine, or -2400 mOsm/L NaCl solution made up of 7.5 g/100 ml NaCl or an equal solute dose (48 ml/kg) of isotonic lactated Ringer's.
- the later solution is the current large volume isotonic standard of care for treating hemorrhage and brain injury.
- FIG. IB shows the intracranial pressure after administration of the solutions described in FIG. 1 A.
- FIG. 2A shows the resuscitative effects of 6 ml/kg of a -2400 mOsm hypertonic arginine solution containing 7.28 g/100 ml NaCl and 1.67 g L-arginine (HArg) and a second experiment with HArg mixed with 10% alpha alpha free hemoglobin (HArg-Hb) as measured by changes in arterial blood pressure in anesthetized hemorrhaged rats subjected to TBI.
- FIG. 2B shows the changes in brain blood flow in rats administered the solutions described in FIG. 2A.
- FIG. 3 A shows the effects of resuscitation on arterial pressure with 2 ml/kg of 10 g/100 ml of alpha alpha hemoglobin infused into conscious sheep after a 65 minute hemorrhage of 1300 ml. Ten minutes after the hemoglobin infusion the effects of 4 ml/kg of- 2400 mOsm or exactly 7.16 g/100 ml NaCl and 2.5 g/100 ml of L-arginine are shown.
- FIG. 3B shows the effects of resuscitation on cardiac output of the sheep after administration of the solutions described in FIG. 3A.
- FIG. 4A shows the calculated vascular resistance of the systemic circulation (mean arterial pressure divided by cardiac output) of the same sheep in FIGs. 3A and 3B during baseline, hemorrhage, 10 minutes after hemoglobin infusion and 10 minutes after L- arginine infusion.
- FIG. 4B shows the pulmonary vascular resistance (the pulmonary artery pressure and pulmonary wedge pressure difference divided by cardiac output) of the sheep administered the solutions described in FIG. 3A.
- HSD has limitations, including:
- HSD increases blood pressure and lowers ICP, but only transiently improves brain CBF
- NaCl and dextran are relatively inert and devoid of specific pharmacologic effects that improve brain blood flow
- HSD dilutes the red cell content and decreases the blood's oxygen content.
- Hyperosmotic Oxygen Carriers The present invention has approached the resuscitation problem by combining a hyperosmotic solution with an oxygen carrier in one embodiment.
- Hypertonic oxygen carriers have been described in several publications and patents including hyperosmotic crystalloid-hyperoncotic colloid combinations such as, - 2400 mOsm NaCl- combined with protein such as hyperoncotic hemoglobin, (Kramer and Holcroft 1985); hypertonic solutions mixed with oxygen carrying perfluorocarbons or hemoglobins, (Runge 1989); hypertonic saline combined with liposome encapsulated hemoglobin (Rabinovici, 1993); and specific hypertonic sodium acetate chloride vasodilatory formulations combined with hemoglobin, (Rocha e Silva, Velasco and Kramer 1993; and Rocha e Silva, Velasco and Kramer and Wade, 1995).
- the hemoglobin molecule is similar in size to dextran, but carries oxygen. In solution, hemoglobin concentrations of 5 g/100 ml and above produces a hyperoncotic formulation.
- a key physiologic role of the hyperosmotic crystalloid is to rapidly expand plasma volume due to osmotic induced movement of cellular water into the circulation, while a key role for the hyperoncotic macromolecular colloid is to hold that water in the circulation, (Kramer/Holcroft, 1985).
- a - 2400 mOsm L solution has been shown to be a highly effective concentration for the hyperosmotic crystalloid component, (Kramer, 1997).
- hypertonic acetate hemoglobin would be desirable because of the strong vasodilatory properties of the acetate which can oppose the vasoconstriction of hemoglobin (Rocha e Silva, Velasco, Kramer and Wade, 1995). Additionally, it was known that such solutions combine the cardiovascular attributes of hyperosmotic-hyperoncotic solutions (rapid volume expansion, vasodilation, reduced afterload, increased contractility, reduction of cellular edema) with the oxygen carrying augmentation of hemoglobin. However, the inventors were also aware that these previously described hypertonic oxygen carrying solutions generally make use of relatively inert NaCl or sugar solutions as their osmotic agent and are devoid of any properties that selectively improved CBF. (Kramer and Holcroft 1985; Rabinovici, 1993; Runge, 1994).
- L-arginine was reported to negate the beneficial resuscitative effects of hemoglobin (Sharma, 1995). Sharma et al, suggested that NO inhibition was required for the full beneficial effects of hemoglobin to be apparent. Isotonic arginine has been shown to reduce some of the vasoconstriction of hemoglobin. Rats infused with diaspirin alpha alpha cross-linked hemoglobin exhibited increased arterial blood pressure, which was returned to pre-hemoglobin levels by a 600 mg/kg dose of L-arginine (Katsuyama, 1994).
- compositions may be used to effectively treat circulatory shock associated with decreased brain blood as occurs with traumatic head injury.
- Hemorrhagic shock is a common form of circulatory shock in which half or more of estimated blood volume (6% of body weight) is lost.
- blood volume 6% of body weight
- "Standard of care" treatment as set forth by the American College of Surgeons is to restore blood volume with large volume of isotonic crystalloid such as lactated Ringers or normal (0.9%) saline.
- resuscitative volumes equal to 3 times hemorrhaged blood volume are needed or six liters in this example.
- arginine/sodium chloride solutions are used as initial or early treatment of shock and traumatic brain injury in small volume doses of about 4-6 ml/Kg or about 250ml to 500ml in this example.
- the hypertonic L-arginine compositions may also be administered parenterally, for example by intravenous infusion.
- Solutions of the free base or pharmacologically acceptable salts can be prepared in water.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of pyrogen free, sterile manufacture and storage.
- Sterile infusible solutions are prepared by incorporating the L-arginine in the required amount in the appropriate hypertonic aqueous solvent with various of the other enumerated below, as required, followed by filtered sterilization.
- the preferred methods of preparation are vacuum- drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- pharmaceutically and physiologically acceptable refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human.
- the preparation of an aqueous composition that contains salts, proteins, carbohydrates or amino acids as active ingredients are well understood in the art.
- such compositions are prepared as injectables, either as liquid solutions; solid forms suitable for solution in, liquid prior to injection can also be prepared.
- the preparation can also be emulsified.
- composition can be formulated in a neutral or salt form.
- Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the L- arginine) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like.
- Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
- inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
- solutions Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
- the formulations are easily administered in a variety of dosage forms such as injectable solutions and the like.
- Example 1 This example illustrates the effect of L-arginine in a rat injury model. It has been shown that CBF decreases significantly within 15 minutes after experimental TBI in rats (Yuan, 1988). Thus, experimental injury models in rats are well-suited for studying the mechanisms that contribute to post-traumatic cerebral hypoperfusion.
- rats were treated after moderate TBI with L-arginine (100 mg/kg, i.v., 5 min post-TBI)
- This example illustrates the beneficial effect of hyperosmotic arginine solutions in treating hemorrhagic shock in an animal model.
- Standard of care treatments of TBI and hemorrhage with large volume isotonic therapy has often been shown to inadequately restore arterial pressure, elevate ICP and cause sustained reductions in CBF.
- This experiment shows that a small volume IV infusion of- 2400 mOsm Arginine NaCl solution (7.28 g NaCl and 1.67 g/100 ml L-arginine) lowers ICP and improves CBF better than small volume 2,400 mOsm NaCl or large volume of isotonic "standard of care" resuscitation.
- Three rats per group were anesthetized with isoflurane and had arterial and venous catheters placed for bleeding, infusion, and pressure monitoring.
- a laser Doppler flow probe was placed above the dura to allow monitoring of CBF and a intracranial pressure catheter was placed to allow measurement of intracranial pressure.
- a moderate (1.5 atmosphere) percussion injury was administered through a fluid column connected by catheter which had been cemented through the skull to the dura.
- Five minutes later blood pressure was reduced to 60 mmHg for 30 minutes by bleeding.
- the hemorrhage and brain injury reduced CBF 30 to 70% from its baseline levels.
- FIG. 1A shows elevated ICP after lactated Ringer's treatment and lower ICP with hypertonic saline and particularly with hypertonic arginine.
- FIG. IB also shows higher
- Example 3 Using the same animal model described in Example 1 , a hypertonic arginine alpha cross-linked hemoglobin oxygen carrying colloid solution was infused through a venous catheter to treat hemorrhagic shock in three TBI rats.
- the solution of the hyperosmotic crystalloid was 7.28 g/lOOml NaCl and 1.67g/100ml L-arginine, while the hemoglobin was lOg/lOOml free human hemoglobin modified by cross-linking between the alpha subunits with bis-(3,5-dibromosalicyl) fumarate (alpha alpha Hb) and prepared according to previously published methods, (Winslow, 1992).
- the small volume solutions were infused evenly over 6 minutes.
- FIGs. 2A and 2B show higher CBF and blood pressure after TBI and hemorrhage when treated with a 6 ml/kg intravenous infusion of hypertonic -2,400 mOsm arginine hemoglobin solution compared to hypertonic arginine alone. Both of the hypertonic arginine solutions were more effective than equal volume of hypertonic saline or a larger volume of lactated Ringer's, FIGs 1A and IB.
- Example 4 This example shows that hypertonic arginine solutions may be used to treat the systemic and pulmonary vasoconstriction of hemoglobin infusions and improve the resuscitative properties of hemoglobin containing blood substitutes. This illustrates how a hyperosmotic arginine solution could be used to treat the deleterious vasoconstriction of hemoglobin solutions or suggests that a premixed or concurrently delivered dose of hyperosmotic arginine with hemoglobin would be a most effect resuscitation solution.
- FIGs. 3A and 3B A 44 kg sheep was subjected to a 1300 ml hemorrhage over 65 minutes which reduced cardiac output and blood pressure, FIGs. 3A and 3B.
- FIGs. 3A and 3B A subsequent infusion of 4 ml/kg of a - 2400 mOsm/L hypertonic arginine solution made up of 7.16 g/100 ml of NaCl and 2.5 g/100 ml of L-arginine had little effect on blood pressure, but improved and returned cardiac output towards normal, FIGs. 3A and 3B and reduced the vasoconstriction in systemic and pulmonary circulation, FIGs. 4A and 4B.
- Such improved cardiac output would be expected to result in superior blood flow and oxygen delivery to most organs.
- This example shows several hypertonic arginine formulations that will be useful for treatment of trauma and shock. These are illustrated by the following:
- various hyperoncotic colloids such as dextran, hespan, and other macromolecules such as hemoglobin.
- Such solutions may be used to treat trauma, hemorrhage, TBI, dehydration, heat stress, spinal cord injury, subarachnoid hemorrhage, in the vasoconstriction of other conditions such as migraine, and in others conditions of cerebral ischemia such as cardiac surgery.
- a - 2400 mOsm/L concentration of a mixture of hypertonic crystalloid NaCl/Arginine is made from the following g/100 ml concentrations to deliver an effective dose in a 4 ml/kg infusion:
- the -2400 mOsm/L solution could be made from the following g/100 ml concentrations:
- Such hypertonic crystalloids are contemplated as particularly useful solutions when combined with a colloid or an oxygen carrier such as hemoglobin, fluorocarbon, or similar combination.
- the hypertonic crystalloid formulations of Table 1 or Table 2 with an oxygen carrying hemoglobin or fluorocarbon would provide an effective solution, particularly when the solution is also hyperoncotic due to a macromolecular colloid component as shown in Table 3.
- Free hemoglobin solutions at concentrations above 5% or 5g/100 ml are normally hyperoncotic.
- Hemoglobin encapsulated in liposomes or vesicles or fluorocarbon solutions do not generate significant oncotic pressure and would benefit from the addition of a colloid to produce a hyperoncotic solution.
- the hyperosmotic NaCl-Arginine crystalloid formulations of Table 1 and 2 could be made-up as hyperoncotic colloids by adding the following concentrations of hemoglobin, dextran, hespan or other macromolecular plasma expanders.
- Crystalloid Oxygen Hyperoncotic -2400 mOsm L
- Carrier Colloid concentration in g/100 ml
- Cerebral vasospasm a severe narrowing of the cerebral arteries, is a major cause of mortality and morbidity in patients after subarachnoid hemorrhage. Expansion of intravascular volume is one of the standard methods of treatment of vasospasm (Heros and Zervas, 1983). Recent evidence indicates that L-arginine dilates cerebral arteries (Morikawa, et al., 1994) and reduces the vasoconstriction of experimental vasospasm due to subarachnoid hemorrhage (Kajita, et al., 1994).
- compositions, methods and/or apparatus disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions, methods and apparatus and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
- L-arginine or superoxide dismutase prevents or reverses cerebral hypoperfusion after fluid- percussion traumatic brain injury. J Neurotrauma 1997; 14(4):223-33.
- Poli de Figueiredo LF Mathru M, Solanki D, MacDonald VW, Hess J, Kramer GC. Pulmonary hypertension and systemic vasoconstriction may offset the benefits of acellular hemoglobin blood substitutes. J Trauma 42(5):847-57, 1997b.
- Poli de Figueiredo LF Elgjo GI, Mathru M, Rocha e Silva M, Kramer GC. Hypertonic acetate-alpha-alpha hemoglobin for small volume resuscitation of hemorrhagic shock. Artif Cells Blood Substit Immobil 25(l&2):61-73, 1997a.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU43448/97A AU4344897A (en) | 1996-08-26 | 1997-08-26 | Hypertonic arginine compositions and methods |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2579396P | 1996-08-26 | 1996-08-26 | |
US60/025,793 | 1996-08-26 | ||
US2579397P | 1997-08-26 | 1997-08-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998008500A1 true WO1998008500A1 (en) | 1998-03-05 |
Family
ID=26700155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/016203 WO1998008500A1 (en) | 1996-08-26 | 1997-08-26 | Hypertonic arginine compositions and methods |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1998008500A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999043308A2 (en) * | 1998-02-27 | 1999-09-02 | Marlene Rabinovitch | Treating pulmonary hypertension through tenascin suppression and elastase inhibition |
EP1175210A1 (en) * | 1999-03-19 | 2002-01-30 | Enos Pharmaceuticals, Inc. | Increasing cerebral bioavailability of drugs |
EP1466649A1 (en) * | 2003-04-08 | 2004-10-13 | Nipro Corporation | Pharmaceutical composition containing artificial oxygen carrier |
EP1472280A2 (en) * | 2002-01-11 | 2004-11-03 | Sangart, Inc. | Methods and compositions for oxygen transport comprising an oxygen carrier and a crystalloid in hypertonic solution |
WO2004096204A1 (en) * | 2003-05-01 | 2004-11-11 | Innogene Kalbiotech Pte Ltd | Lactate containing pharmaceutical composition and uses thereof |
US6986905B1 (en) * | 1998-05-15 | 2006-01-17 | Chaoying Zhao | Pharmaceutical compositions for treating and saving and the method for the preparation thereof |
EP2099463A2 (en) * | 2006-11-07 | 2009-09-16 | The General Hospital Corporation | Attenuation of vasoactive oxygen carrier-induced vasoconstriction |
US20130324608A1 (en) * | 2011-02-18 | 2013-12-05 | Yuanlong Pan | Methods and compositions for treating, reducing or preventing damage to the nervous system of animals |
US9572833B2 (en) | 2011-11-07 | 2017-02-21 | The General Hospital Corporation | Treatment of red blood cells |
FR3088193A1 (en) * | 2018-11-13 | 2020-05-15 | Andrea Fox | AQUEOUS COMPOSITION, MANUFACTURING METHOD THEREOF, AND NASAL ADMINISTRATION DEVICE |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5217997A (en) * | 1990-01-09 | 1993-06-08 | Levere Richard D | Use of l-arginine in the treatment of hypertension and other vascular disorders |
US5443848A (en) * | 1991-05-31 | 1995-08-22 | Board Of Regents, The University Of Texas System | Hypertonic isochloremic formulations for treatment of hypovolemic and circulatory shock |
-
1997
- 1997-08-26 WO PCT/US1997/016203 patent/WO1998008500A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5217997A (en) * | 1990-01-09 | 1993-06-08 | Levere Richard D | Use of l-arginine in the treatment of hypertension and other vascular disorders |
US5443848A (en) * | 1991-05-31 | 1995-08-22 | Board Of Regents, The University Of Texas System | Hypertonic isochloremic formulations for treatment of hypovolemic and circulatory shock |
Non-Patent Citations (2)
Title |
---|
AMERICAN JOURNAL OF PHYSIOLOGY, 1995, Vol. 269, No. 4, Pt. 2, SHARMA et al., "Role of NO Mechanism in Cardiovascular Effects of Diaspirin Cross-Linked Hemoglobin in Anesthetized Rats", pages H1379-H1388. * |
ANESTHESIOLOGY, February 1993, Vol. 78, No. 2, COLE et al., "Focal Cerebral Ischemia in Rats Effects of Hypervolemic Hemodilution with Diaspirin Cross-Linked Hemoglobin Versus Albumin on Brain Injury and Edema", pages 335-342. * |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999043308A3 (en) * | 1998-02-27 | 1999-10-28 | Marlene Rabinovitch | Treating pulmonary hypertension through tenascin suppression and elastase inhibition |
WO1999043308A2 (en) * | 1998-02-27 | 1999-09-02 | Marlene Rabinovitch | Treating pulmonary hypertension through tenascin suppression and elastase inhibition |
US6986905B1 (en) * | 1998-05-15 | 2006-01-17 | Chaoying Zhao | Pharmaceutical compositions for treating and saving and the method for the preparation thereof |
EP1175210A1 (en) * | 1999-03-19 | 2002-01-30 | Enos Pharmaceuticals, Inc. | Increasing cerebral bioavailability of drugs |
EP1175210A4 (en) * | 1999-03-19 | 2003-07-09 | Enos Pharmaceuticals Inc | Increasing cerebral bioavailability of drugs |
US6818669B2 (en) | 1999-03-19 | 2004-11-16 | Enos Pharmaceuticals, Inc. | Increasing cerebral bioavailability of drugs |
EP1472280A2 (en) * | 2002-01-11 | 2004-11-03 | Sangart, Inc. | Methods and compositions for oxygen transport comprising an oxygen carrier and a crystalloid in hypertonic solution |
EP1472280A4 (en) * | 2002-01-11 | 2005-09-21 | Sangart Inc | Methods and compositions for oxygen transport comprising an oxygen carrier and a crystalloid in hypertonic solution |
US7417118B2 (en) | 2003-04-08 | 2008-08-26 | Nipro Corporation | Pharmaceutical composition containing artificial oxygen carrier |
EP1466649A1 (en) * | 2003-04-08 | 2004-10-13 | Nipro Corporation | Pharmaceutical composition containing artificial oxygen carrier |
EA010948B1 (en) * | 2003-05-01 | 2008-12-30 | Инноджен Калбиотех Пте Лтд. | Lactate containing pharmaceutical composition and uses thereof |
EP1759695A1 (en) * | 2003-05-01 | 2007-03-07 | Innogene Kalbiotech Pte. Ltd. | Lactate containing pharmaceutical composition and uses thereof |
WO2004096204A1 (en) * | 2003-05-01 | 2004-11-11 | Innogene Kalbiotech Pte Ltd | Lactate containing pharmaceutical composition and uses thereof |
US8887721B2 (en) | 2006-11-07 | 2014-11-18 | The General Hospital Corporation | Attenuation of vasoactive oxygen carrier-induced vasoconstriction |
JP2010509353A (en) * | 2006-11-07 | 2010-03-25 | ザ ジェネラル ホスピタル コーポレイション | Attenuation of vasoconstriction induced by vasoactive oxygen carriers |
EP2099463A4 (en) * | 2006-11-07 | 2010-04-21 | Gen Hospital Corp | Attenuation of vasoactive oxygen carrier-induced vasoconstriction |
EP2099463A2 (en) * | 2006-11-07 | 2009-09-16 | The General Hospital Corporation | Attenuation of vasoactive oxygen carrier-induced vasoconstriction |
US20130324608A1 (en) * | 2011-02-18 | 2013-12-05 | Yuanlong Pan | Methods and compositions for treating, reducing or preventing damage to the nervous system of animals |
US9572833B2 (en) | 2011-11-07 | 2017-02-21 | The General Hospital Corporation | Treatment of red blood cells |
FR3088193A1 (en) * | 2018-11-13 | 2020-05-15 | Andrea Fox | AQUEOUS COMPOSITION, MANUFACTURING METHOD THEREOF, AND NASAL ADMINISTRATION DEVICE |
WO2020099264A1 (en) | 2018-11-13 | 2020-05-22 | Djellouli Said | Aqueous saline composition, process for the production of same, and use of same |
CN112739324A (en) * | 2018-11-13 | 2021-04-30 | 赛义德·贾卢利 | Brine composition, method for producing same and use thereof |
US20210299171A1 (en) * | 2018-11-13 | 2021-09-30 | Saïd DJELLOULI | Aqueous saline composition, process for the production of same, and use of same |
US11878032B2 (en) | 2018-11-13 | 2024-01-23 | Saïd DJELLOULI | Aqueous saline composition, process for the production of same, and use of same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2992855B2 (en) | Administration of low-dose hemoglobin to increase perfusion | |
US7309502B2 (en) | Pharmaceutical compositions for treating and saving and the method for the preparation thereof | |
ES2274438T3 (en) | USE OF A PHARMACEUTICAL COMMISSION CONTAINING LACTIC ACID OR LACTATE AND POTASSIUM TO TREAT CEREBRAL EDEMA OR BRAIN INJURIES. | |
US4981691A (en) | Oxygenated fluorocarbon nutrient solution | |
EP0587815B1 (en) | Hypertonic isochloremic formulation for circulatory shock | |
US8552068B2 (en) | Compositions and methods | |
BG62913B1 (en) | Improved concentrated inoculation and infusion solutions for intravasal application | |
US5945272A (en) | Plasma expanders and blood substitutes | |
WO1998008500A1 (en) | Hypertonic arginine compositions and methods | |
BRPI0621528A2 (en) | pharmaceutical composition containing lactate and calcium, and uses thereof | |
Maningas et al. | Hypertonic sodium chloride solutions for the prehospital management of traumatic hemorrhagic shock: a possible improvement in the standard of care? | |
US20100144597A1 (en) | Novel combinatorial approaches to enhancing oxygen transport to tissues | |
WO1995034301A1 (en) | Energy substrates | |
Kien et al. | Hypertonic saline: Current research and clinical implications | |
Swingle et al. | A study of gelatin and saline as plasma substitutes | |
JP2024023386A (en) | Compositions and devices for systemic delivery of uridine | |
JPH05507709A (en) | Hypertonic solution for emergency resuscitation with no change in blood sodium level | |
Umbarkar | Recent innovations in myocardial protection strategies during cardiac surgeries | |
Kramer et al. | Recent trends in fluid therapy | |
Vincent et al. | Crystalloids versus colloids in septic shock | |
Hahn | Clinical pharmacology of infusion fluids | |
Friedberg | Treatment of SHOCK in Acute Myocardial Infarction: Second of two parts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09256821 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998512018 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |